Phase I/II Trial of Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination with HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants with Advanced or Metastatic Endometrial Cancer (EC)
Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens into the Human Lung (En español)
Researchers at the National Heart, Lung, and Blood Institute in Bethesda, Maryland, are conducting a study to evaluate the airway immunity in adults with a positive TB skin or blood test. With this study, researchers hope to discover better prevention and treatments for TB. (En español)
Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens into the Human Lung
Studies of the Natural History of Sickle Cell Disease
The research study aims to enhance the understanding of SCD and its associated complications by investigating the relationship between the disease and specific variations of certain genes. If you have SCD, your participation in this study is highly valuable. By participating, you will undergo an evaluation and receive recommendations from a team experienced in the treatment and management of SCD.
Diabetes and Heart Disease Risk in Blacks
A study at NIH is recruiting healthy African Americans and African-born individuals to better understand diabetes and heart disease risk in Black populations. If you are African American or African-born Black between the ages of 18 and 70 years.
Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer (En español)
Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer. (En español)
Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer
Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer.